Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is the assessment of the overall graft rejection rate (acute,
chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to
standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a
treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year
after renal transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
Neovii Biotech
Collaborators:
Eurotrials Brasil Consultores Cientificos Ltda PsyConsult Recerca Clínica S.L.